Center for Health and Community, University of California, San Francisco.
Department of Epidemiology and Population Health, Stanford University School of Medicine, Palo Alto, California.
JAMA Netw Open. 2021 Mar 1;4(3):e211955. doi: 10.1001/jamanetworkopen.2021.1955.
State cannabis laws are changing rapidly. Research is inconclusive about their association with rates of self-harm and assault. Existing studies have not considered variations in cannabis commercialization across states over time.
To evaluate the association of state medical and recreational cannabis laws with self-harm and assault, overall and by age and sex, while considering varying degrees of commercialization.
DESIGN, SETTING, AND PARTICIPANTS: Using a cohort design with panel fixed-effects analysis, within-state changes in claims for self-harm and assault injuries before and after changes in cannabis laws were quantified in all 50 US states and the District of Columbia. Comprehensive claims data on commercial and Medicare Advantage health plan beneficiaries from January 1, 2003, to December 31, 2017, grouped by state and month, were evaluated. Data analysis was conducted from January 31, 2020, to January 21, 2021.
Categorical variable that indexed the degree of cannabis legalization in each state and month based on law type (medical or recreational) and operational status of dispensaries (commercialization).
Claims for self-harm and assault injuries based on International Classification of Diseases codes.
The analysis included 75 395 344 beneficiaries (mean [SD] age, 47 [22] years; 50% female; and median follow-up, 17 months [interquartile range, 8-36 months]). During the study period, 29 states permitted use of medical cannabis and 11 permitted recreational cannabis. Point estimates for populationwide rates of self-harm and assault injuries were higher in states legalizing recreational cannabis compared with states with no cannabis laws, but these results were not statistically significant (adjusted rate ratio [aRR] assault, recreational dispensaries: 1.27; 95% CI, 0.79-2.03;self-harm, recreational dispensaries aRR: 1.15; 95% CI, 0.89-1.50). Results varied by age and sex with no associations found except for states with recreational policies and self-harm among males younger than 40 years (aRR <21 years, recreational without dispensaries: 1.70; 95% CI, 1.11-2.61; aRR aged 21-39 years, recreational dispensaries: 1.46; 95% CI, 1.01-2.12). Medical cannabis was generally not associated with self-harm or assault injuries populationwide or among age and sex subgroups.
Recreational cannabis legalization appears to be associated with relative increases in rates of claims for self-harm among male health plan beneficiaries younger than 40 years. There was no association between cannabis legalization and self-harm or assault, for any other age and sex group or for medical cannabis. States that legalize but still constrain commercialization may be better positioned to protect younger male populations from unintended harms.
州级大麻法律正在迅速变化。关于这些法律与自残和攻击率之间的关联,研究结果尚无定论。现有研究尚未考虑到各州大麻商业化程度随时间的变化。
评估州级医疗和娱乐用大麻法律与自残和攻击的关联,总体上以及按年龄和性别进行评估,同时考虑到不同程度的商业化。
设计、设置和参与者:使用队列设计和面板固定效应分析,在所有 50 个美国州和哥伦比亚特区,量化了大麻法律变更前后与自我伤害和攻击伤害相关的索赔,根据州和月份进行了分组。评估了 2003 年 1 月 1 日至 2017 年 12 月 31 日商业和 Medicare Advantage 健康计划受益人的综合索赔数据,这些数据按州和月份进行了分组。数据分析于 2020 年 1 月 31 日至 2021 年 1 月 21 日进行。
根据法律类型(医疗或娱乐)和药房运营状态(商业化),对每个州和月份的大麻合法化程度进行分类的类别变量。
根据国际疾病分类代码对自我伤害和攻击伤害的索赔。
分析包括 75395344 名受益人(平均[SD]年龄,47[22]岁;50%为女性;中位随访时间为 17 个月[四分位间距,8-36 个月])。在研究期间,29 个州允许使用医用大麻,11 个州允许使用娱乐用大麻。与没有大麻法律的州相比,在允许使用娱乐用大麻的州,自残和攻击伤害的人群发生率较高,但这些结果无统计学意义(调整后的发病率比[ARR],娱乐用药房:1.27;95%CI,0.79-2.03;自残,娱乐用药房:ARR 1.15;95%CI,0.89-1.50)。结果因年龄和性别而异,除了在允许娱乐用大麻政策和 40 岁以下男性中发现自残没有关联外(21 岁以下,无药房的娱乐用大麻:1.70;95%CI,1.11-2.61;21-39 岁,有药房的娱乐用大麻:1.46;95%CI,1.01-2.12)。总体而言,医用大麻与自残或攻击伤害无关,无论年龄和性别亚组。
娱乐用大麻合法化似乎与 40 岁以下男性健康计划受益人的自残索赔率相对增加有关。对于任何其他年龄和性别群体或医用大麻,大麻合法化与自残或攻击之间均无关联。合法化但仍限制商业化的州可能更有能力保护年轻男性免受意外伤害。